These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9396471)

  • 1. Etomoxir improves left ventricular performance of pressure-overloaded rat heart.
    Turcani M; Rupp H
    Circulation; 1997 Nov; 96(10):3681-6. PubMed ID: 9396471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of left ventricular hypertrophy by chronic etomixir treatment.
    Turcani M; Rupp H
    Br J Pharmacol; 1999 Jan; 126(2):501-7. PubMed ID: 10077244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tedisamil attenuates foetal transformation of myosin in the hypertrophied rat myocardium.
    Turcani M; Thormaehlen D; Rupp H
    Br J Pharmacol; 2004 Nov; 143(5):561-72. PubMed ID: 15466442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarcoplasmic reticulum function and carnitine palmitoyltransferase-1 inhibition during progression of heart failure.
    Rupp H; Vetter R
    Br J Pharmacol; 2000 Dec; 131(8):1748-56. PubMed ID: 11139455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of pressure overload induced cardiac hypertrophy is unaffected by long-term treatment with losartan.
    Turcani M; Rupp H
    Mol Cell Biochem; 1998 Nov; 188(1-2):225-33. PubMed ID: 9823028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of subcellular organelles in pressure-overloaded heart by etomoxir, a carnitine palmitoyltransferase I inhibitor.
    Rupp H; Elimban V; Dhalla NS
    FASEB J; 1992 Mar; 6(6):2349-53. PubMed ID: 1531968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo.
    Schwarzer M; Faerber G; Rueckauer T; Blum D; Pytel G; Mohr FW; Doenst T
    Basic Res Cardiol; 2009 Sep; 104(5):547-57. PubMed ID: 19294446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcellular remodeling and heart dysfunction in cardiac hypertrophy due to pressure overload.
    Dhalla NS; Golfman L; Liu X; Sasaki H; Elimban V; Rupp H
    Ann N Y Acad Sci; 1999 Jun; 874():100-10. PubMed ID: 10415524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial contractility after infarction and carnitine palmitoyltransferase I inhibition in rats.
    Günther J; Wagner K; Theres H; Schimke I; Born A; Scholz H; Vetter R
    Eur J Pharmacol; 2000 Oct; 406(1):123-6. PubMed ID: 11011043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of heart function and Na+-K+-ATPase activity by etomoxir in diabetic rats.
    Kato K; Chapman DC; Rupp H; Lukas A; Dhalla NS
    J Appl Physiol (1985); 1999 Mar; 86(3):812-8. PubMed ID: 10066690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CPT-1 inhibition by etomoxir has a chamber-related action on cardiac sarcoplasmic reticulum and isomyosins.
    Vetter R; Rupp H
    Am J Physiol; 1994 Dec; 267(6 Pt 2):H2091-9. PubMed ID: 7810710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target.
    Zarain-Herzberg A; Rupp H
    Expert Opin Investig Drugs; 2002 Mar; 11(3):345-56. PubMed ID: 11866664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary medium-chain triglycerides can prevent changes in myosin and SR due to CPT-1 inhibition by etomoxir.
    Rupp H; Schulze W; Vetter R
    Am J Physiol; 1995 Sep; 269(3 Pt 2):R630-40. PubMed ID: 7573566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor Etomoxir.
    Schmitz FJ; Rösen P; Reinauer H
    Horm Metab Res; 1995 Dec; 27(12):515-22. PubMed ID: 8750778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential influences of carnitine palmitoyltransferase-1 inhibition and hyperthyroidism on cardiac growth and sarcoplasmic reticulum phosphorylation.
    Vetter R; Kott M; Rupp H
    Eur Heart J; 1995 May; 16 Suppl C():15-9. PubMed ID: 7556265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial protection from ischemic preconditioning is not blocked by sub-chronic inhibition of carnitine palmitoyltransferase I.
    Penna C; Mancardi D; Gattullo D; Pagliaro P
    Life Sci; 2005 Sep; 77(16):2004-17. PubMed ID: 15919095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocardial contractility and ventricular myosin isoenzymes as influenced by cardiac hypertrophy and its regression.
    Tanamura A; Takeda N; Iwai T; Tuchiya M; Arino T; Nagano M
    Basic Res Cardiol; 1993; 88(1):72-9. PubMed ID: 8471005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First clinical trial with etomoxir in patients with chronic congestive heart failure.
    Schmidt-Schweda S; Holubarsch C
    Clin Sci (Lond); 2000 Jul; 99(1):27-35. PubMed ID: 10887055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contractile function, myosin ATPase activity and isozymes in the hypertrophied pig left ventricle after a chronic progressive pressure overload.
    Wisenbaugh T; Allen P; Cooper G; Holzgrefe H; Beller G; Carabello B
    Circ Res; 1983 Sep; 53(3):332-41. PubMed ID: 6224606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac contractile proteins in hypertrophied and failing guinea pig heart.
    Malhotra A; Siri FM; Aronson R
    Cardiovasc Res; 1992 Feb; 26(2):153-61. PubMed ID: 1533346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.